API Manufacturer vs Distributor vs CDMO: Which to Use?

Use three questions: Is the molecule established, can you trace the original manufacturing site, and does the process need development? Choose a manufacturer for an established API, a distributor for qualified inventory with a complete batch trail, and a CDMO for development or process transfer.

For a US buyer, the supplier’s label matters less than the evidence behind the exact molecule. Your purchase path must connect the material, manufacturing site, batch documents, filing route, importer, and change-control responsibilities.

Choose Your API Sourcing Model

Start with the molecule and the work still required. The table below gives the practical first choice for most procurement teams.

Choose the first row that matches your program. Move to a CDMO when your process is unsettled. Use a distributor only when the distributor can preserve the original manufacturer’s full evidence trail.

API Manufacturer, Distributor, or CDMO: What Is the Difference?

An API manufacturer is the organization behind the named site that makes the drug substance. An API distributor supplies material from that manufacturer through a documented commercial and logistics channel. An API CDMO develops or manufactures an API under a customer-defined project.

The labels can overlap. FDA’s GMP guidance defines API manufacturing broadly enough to include receipt, production, packaging, quality control, release, storage, and distribution. FDA Q7 guidance That is why a buyer should ask, “Who made this batch at which site?” before relying on a supplier’s title.

A manufacturer is usually the strongest starting point for a mature API. The buyer can discuss the molecule directly with the site responsible for its process, quality system, capacity, and changes.

A distributor is useful when it solves a real supply problem. That may include access to qualified inventory, local handling, or a simpler import channel. The distributor must still identify the original manufacturer and preserve the batch evidence.

A CDMO is a development partner, not simply a seller of bulk API. Use one when the route, process, analytical methods, scale, or technology transfer requires technical work before routine supply can begin.

When Should You Buy Directly from an API Manufacturer?

Buy directly when your finished product already uses a defined API specification and you need ongoing supply from a named manufacturing site.

Ask the manufacturer for the proposed site, current product status, batch-specific Certificate of Analysis, specification, retest or expiry date, annual capacity discussion, and written change-notification process. A product catalog can help you build a longlist. It does not prove that the listed molecule is externally available for your market.

For a US filing, ask whether the exact API has a Type II Drug Master File path and whether the holder can provide a Letter of Authorization. A Type II DMF can contain confidential drug-substance information, but FDA reviews it only when an applicant references it with an LOA. FDA DMF rules

Our rule of thumb: choose direct manufacturer sourcing when you can name the site, identify the batch records, and define the commercial demand before requesting a quote. Use our API manufacturing capability checklist to turn those requirements into an RFQ.

When Is an API Distributor the Better Option?

Use a distributor when the molecule is already established and the distributor gives you a controlled path to qualified material. The distributor is not a substitute for knowing who manufactured the API.

ICH Q7 says an agent, broker, trader, distributor, repacker, or relabeler should provide the original manufacturer’s identity and the supplied batch number. The same guidance requires transfer of quality and regulatory information between manufacturer and customer. ICH Q7 requirements

Request these records before accepting a distributor-supplied batch:

• Original manufacturer name and manufacturing-site address.
• Original manufacturer batch number.
• Authentic original manufacturer CoA.
• Distributor storage and transport records.
• Retest or expiry date.
• Complaint, recall, and change-notification route.
• Written authorization to supply the manufacturer’s material.

The CoA must identify the API, batch, release date, and test results. It should also show the original manufacturer’s details. CoA requirements

For imported material, FDA requires foreign API manufacturers, repackers, relabelers, and salvagers to register and list commercially distributed APIs. Foreign registrants must also identify known importers. FDA import rules Map those legal entities before you award the purchase order.

For a practical US import review, use this API importer qualification map.

When Does an API CDMO Become Necessary?

Use an API CDMO when you need more than an established bulk material. Common triggers include process development, route optimization, impurity control, analytical method development, technology transfer, pilot batches, scale-up, or custom manufacturing.

An API CDMO should be selected for its molecule-specific technical fit. A small-molecule facility may not fit a peptide program. A peptide facility may not fit high-containment steroid chemistry. Ask which development, analytical, manufacturing, and commercial activities the proposed site will perform.

Your CDMO scope should name:

1. The target molecule and required specification.
2. The development deliverables and decision points.
3. The analytical method work and release testing.
4. The technology-transfer responsibilities.
5. The pilot, clinical, and commercial scale plan.
6. The quality agreement and change-control process.
7. The regulatory dossier and LOA route for the intended market.

Do not treat “end-to-end” as a scope. The scope must identify the actual site, work package, batch objective, ownership of development data, and next commercial decision.

Peptide programs often need this deeper process review early. Start with how to choose a peptide CDMO by stage.

Which Documents Should Each Supplier Type Provide?

Every sourcing model starts with the same batch-level evidence. The differences appear when the material changes hands or the process is still being developed.

For a released API batch, request the CoA, specification, batch number, release date, retest or expiry date, and storage conditions. ICH Q7 says the CoA should list each test, its acceptance limit, and the numerical result where applicable. ICH CoA standard

For a distributor, add the original manufacturer’s CoA, storage and transport records, manufacturer identity, and recall route. If the distributor repacks the API, the repackaging controls become part of your qualification review.

For a CDMO, add the project scope, development reports, analytical method plan, technology-transfer plan, quality agreement, scale-up strategy, and commercial supply plan. If the API will support a US ANDA, the DMF holder must authorize FDA to refer to the relevant DMF information through an LOA. FDA LOA process

A complete export package also needs a clear handoff from batch release to shipment. Use this API export dossier guide when procurement, quality, and logistics teams need one shared document list.

How Cost, Lead Time, and Supply Risk Differ

Compare quotes only after you choose the sourcing model. A low material price cannot answer whether the named site can release the batch, support your filing, allocate future capacity, or maintain the same process.

A direct manufacturer quote works best when the molecule, specification, and demand are stable. Ask the manufacturer to tie the quote to the named site, agreed batch range, production slot, release testing, packaging, and change process.

A distributor quote works best when the distributor can show specific qualified inventory or a documented allocation path. Ask the distributor to identify the original batch, storage history, shipment route, and manufacturer escalation contact.

A CDMO budget works best when the project scope separates development work from GMP manufacturing. Ask the CDMO to show each work package, development decision, transfer milestone, batch objective, and commercial capacity decision.

Supply risk follows the same pattern. Manufacturer risk centers on site capacity and continuity. Distributor risk centers on traceability and allocation. CDMO risk centers on development success, transfer, and scale-up.

Make the Decision Before You Send the RFQ

Use this five-step sequence:

1. Name the API, salt or ester, grade, dosage form, target market, and annual demand.
2. Decide whether the process and analytical methods are already transferable.
3. Select manufacturer, distributor, or CDMO using the decision table.
4. Request the matching evidence package before comparing commercial terms.
5. Put site identity, change control, release responsibility, and importer roles into the quality agreement.

At Aarise Pharma, we support international B2B buyers seeking steroid, peptide, hormone, and general pharmaceutical APIs. Our API page states that each shipment includes a CoA and MSDS, with CPP, DMF, and CEP documentation available on request for the relevant material. Our API supply page is the right starting point for a molecule, documentation, and shipment conversation.

For a broader supplier-selection workflow, read our guide to choosing an active pharmaceutical ingredient supplier.

FAQs

Can One Company Be a Manufacturer, Distributor, and CDMO?

Yes. One company can manufacture its own APIs, distribute APIs from other sites, and run development projects under contract. Ask which role applies to your exact molecule, batch, and site.

The answer changes the evidence you need. A company’s broad service portfolio does not establish the source or regulatory path for a specific API.

Does a Distributor CoA Replace the Original Manufacturer CoA?

No. A distributor-issued document must still preserve the original manufacturer and original batch relationship. ICH Q7 requires authentic original CoAs and original manufacturer information in the distribution record. ICH traceability rules

A distributor may add its own testing record where appropriate. That record does not remove the need for the original batch evidence.

Does a Type II DMF Mean FDA Has Approved the API Supplier?

No. FDA states that a DMF is never approved or disapproved. FDA reviews a DMF only when it is referenced in support of an IND, NDA, ANDA, export application, or another DMF. FDA DMF guidance

For a generic-drug submission, the buyer needs the relevant LOA and a current, molecule-specific regulatory path.

Should a US Buyer Audit the Original Manufacturer When Buying Through a Distributor?

Yes, when the API is critical to your finished product or regulatory filing. The distributor’s quality system matters, but the original manufacturer controls the process that created the API.

Use the distributor review to assess storage, transport, records, and recall handling. Use the manufacturer review to assess the site, process, quality system, and change control.

Can You Change API Manufacturers After an ANDA Filing?

Yes, but the change can affect the drug product’s regulatory submission and quality strategy. The new manufacturer, process, DMF support, impurity profile, and documentation must fit the filing requirements.

Plan the alternate source before a supply interruption forces the change.